香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 1518 修訂年度上限及 有關檢查及實驗室測試服務安排之持續關連交易條款的變動 茲提述本公司日期為二零二四年十月四日的公告，內容有關北京新世紀兒童 醫院（本公司非全資附屬公司）與北京兒童醫院之間訂立的安排。根據安排， 北京兒童醫院同意於二零二四年一月一日至二零二六年十二月三十一日期間， 按逐次訂單基準向北京新世紀兒童醫院的患者提供若干檢查和實驗室測試及 相關服務。 董事會謹此宣佈，經訂約方友好磋商，北京新世紀兒童醫院與北京兒童醫 院已同意修訂安排項下的服務範圍及截至二零二五年及二零二六年十二月 三十一日止年度的原年度上限。於本公告日期，安排項下持續關連交易的實 際交易金額並未超出截至二零二五年十二月三十一日止年度的原年度上限。 – 1 – 上市規則涵義 於本公告日期，北京新世紀兒童醫院由嘉華怡和（本公司全資附屬公司）及北 京兒童醫院分別持有65%及35%權益。因此，北京新世紀兒童醫院為本公司 非全資附屬 ...

1518 終止表決協議 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 有權利、義務及責任同時終止。因此，梁女士自終止日期起無須在行使其實益 擁有的本公司股份所附投票權時遵從Zhou先生的投票指示。 股東及潛在投資者在買賣本公司股份時，務請審慎行事。本公司股東及潛在投 資者如有疑問，應徵詢專業或財務顧問的意見。 承董事會命 新世紀醫療控股有限公司 董事長、執行董事兼首席執行官 Jason ZHOU先生 背景 茲提述新世紀醫療控股有限公司（「本公司」）日期為二零一六年十二月三十日 的招股章程，當中提及董事長、首席執行官、執行董事兼本公司控股股東之一 Jason ZHOU先生（「Zhou先生」）與本公司主要股東之一梁艷清女士（「梁女士」） 於二零一六年二月十八日訂立的表決協議（「表決協議」），由協議日期起計初 步為期三年，據此，梁女士不可撤回地同意於表決協議的年期內在行使其實益 擁有的本公司股份所附投票權時遵從Zhou先生的投票指示。該表決協議已透過 多 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 FF301 II. 已發行股份及/或庫存股份變動 致：香港交易及結算所有限公司 公司名稱: 新世紀醫療控股有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01518 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | US ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 新世紀醫療控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01518 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | 本月底法定/註冊股 ...

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 新世紀醫療控股有限公司 呈交日期: 2025年10月9日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01518 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | 本月底法定/註冊股本總額： USD 100,000 股份發行人及根據《上市規則》第十九B章上市的香港 ...

Financial Performance - The company's revenue for the first half of 2025 was RMB 304.5 million, a decrease of 26.8% year-on-year[9] - The company reported a loss attributable to shareholders of RMB 65.2 million for the first half of 2025, compared to a profit of RMB 25.2 million in the same period of 2024[10] - The company recorded a loss of RMB 58.8 million for the six months ended June 30, 2025, compared to a profit of RMB 48.3 million for the same period in 2024, representing a significant decline[33] - The total comprehensive income for the period resulted in a loss of RMB 65,234 thousand, compared to a profit of RMB 25,193 thousand in the same period of 2024[82] - The company reported a net loss of RMB 58,807 thousand for the six months ended June 30, 2025, compared to a profit of RMB 48,307 thousand for the same period in 2024[81] - Basic and diluted loss per share for the period was RMB (0.14), compared to earnings of RMB 0.05 per share in the previous year[81] Revenue Breakdown - Medical service revenue amounted to RMB 301.0 million, down 27.0% year-on-year, with pediatric services contributing RMB 255.7 million, a decline of 29.2%[9] - Pediatric outpatient service revenue was RMB 159.5 million, a decrease of 26.7%, with outpatient visits dropping by 25.6% to 88,045[9] - Pediatric service revenue was RMB 255.7 million, a decrease of 29.2% year-on-year, while obstetric service revenue was RMB 45.3 million, down 11.4%[23] - Revenue from external customers for the pediatric segment was RMB 255,693, for obstetrics and gynecology was RMB 45,312, and for others was RMB 3,523, totaling RMB 304,528 for the six months ended June 30, 2025[93] Cost and Expenses - The cost of revenue for medical services was RMB 209.9 million, a decrease of 13.4% year-on-year[23] - Gross profit for the six months ended June 30, 2025, was RMB 89.6 million, down 46.9% from RMB 168.7 million in the same period last year, with a gross margin of 29.4%[25] - Sales expenses for the six months ended June 30, 2025, were RMB 33.9 million, an increase of 3.4% year-on-year[26] - Administrative expenses decreased by 2.8% year-on-year to RMB 59.1 million[27] - Research and development expenses were RMB 1.8 million, a decrease of 18.2% year-on-year[28] Assets and Liabilities - Non-current assets totaled RMB 424,203 thousand as of June 30, 2025, a decrease of 11.4% from RMB 478,712 thousand as of December 31, 2024[78] - Current assets decreased to RMB 412,579 thousand from RMB 460,422 thousand, reflecting a decline of 10.4%[78] - Total liabilities decreased to RMB 396,449 thousand from RMB 430,258 thousand, a reduction of 7.8%[79] - The company’s total equity decreased to RMB 440,333 thousand from RMB 508,876 thousand, reflecting a decline of 13.4%[79] Cash Flow and Financing - For the six months ended June 30, 2025, the net cash generated from operating activities was RMB 4,844 thousand, a decrease of 92.5% compared to RMB 64,776 thousand for the same period in 2024[83] - The company incurred a net cash outflow from financing activities of RMB 22,065 thousand, compared to RMB 29,169 thousand in the same period of 2024, indicating a 24.5% improvement[83] - Cash and cash equivalents amounted to RMB 331.9 million as of June 30, 2025, a decrease of 6.4% from RMB 354.5 million as of December 31, 2024[37] Shareholder Information - JoeCare holds 150,817,051 shares, representing approximately 30.8% of the company's equity[55] - Victor Gains Limited and Liang Yanqing each hold 57,740,181 shares, accounting for 11.8% of the company's equity[55] - The company has a total of 4,767,500 shares available for grant under the Restricted Share Award Scheme as of June 30, 2025[58] - The Employee Share Scheme has purchased 2,073,500 shares from the market for the benefit of selected participants[60] Corporate Governance - The board of directors has confirmed compliance with all applicable corporate governance code provisions, except for the separation of the roles of Chairman and CEO, which are held by Jason Zhou[65] - A disciplinary action statement was issued by the Stock Exchange on June 11, 2025, citing non-compliance with financial assistance regulations[67] - Relevant executive directors are required to complete 23 hours of training on regulatory and legal issues, while independent non-executive directors must complete 15 hours of similar training[69] Future Plans and Strategies - The company plans to implement a tiered membership card strategy to stabilize renewal rates and maintain the membership base[14] - Focus will be placed on the construction of pediatric sub-specialties and the restructuring of children's healthcare service product lines[14] - The company aims to enhance brand promotion among mid-to-high-end commercial insurance institutions to increase coverage of target customer groups[14] - The implementation of DRG/DIP payment reform is expected to enhance the competitive advantage of private high-end medical institutions[13] Impairment and Provisions - Non-current asset impairment loss was RMB 33.7 million, primarily due to decreased demand for pediatric and obstetric services[29] - The company recognized a provision for impairment of RMB 116,480,000 for receivables from Jia Hua Li Kang as of June 30, 2025[109] - The goodwill impairment loss recognized for the obstetrics cash-generating unit in Beijing was RMB 12,544,000 as of June 30, 2025[104]

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01518 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | 致：香港交易及結算所有限公司 本月底法定/註冊股本總額： USD 100,000 FF301 第 1 頁 共 10 頁 v 1.1.1 公司名稱: 新世紀醫療控股有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年9 ...

Group 1 - The company, New Century Healthcare (01518), reported a revenue of 305 million RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 26.79% [1] - The company recorded a loss attributable to owners of 65.234 million RMB, marking a shift from profit to loss compared to the previous year [1] - The basic loss per share was reported at 0.14 RMB [1]

Core Viewpoint - New Century Healthcare (01518.HK) reported a significant decline in revenue and incurred losses for the six months ending June 30, 2025, primarily due to reduced demand for pediatric and obstetric services [1] Financial Performance - Revenue for the period was RMB 305 million, representing a year-on-year decrease of 26.8% [1] - The loss attributable to the company's owners was RMB 65.234 million, compared to a profit of RMB 25.193 million in the same period last year [1] - Basic loss per share was RMB 0.14 [1] Loss Drivers - The company recorded a pre-tax loss of RMB 41.1 million, contrasting with a pre-tax profit of RMB 72.2 million in the previous year [1] - The decline in revenue was mainly attributed to a decrease in demand for pediatric and obstetric services, resulting in a revenue drop of RMB 111.5 million [1] - Additionally, the company faced impairment losses of RMB 12.5 million related to goodwill and RMB 21.2 million related to property, plant, and equipment [1]

Core Viewpoint - New Century Healthcare (01518) reported a significant loss for the six months ending June 30, 2025, with a shift from profit to loss compared to the previous year [1] Financial Performance - The company achieved revenue of 305 million RMB, representing a year-on-year decrease of 26.79% [1] - The loss attributable to shareholders was 65.234 million RMB, marking a transition from profit to loss compared to the same period last year [1] - Basic loss per share was reported at 0.14 RMB [1]